Prevalence of Endocrinopathies in Beta Thalassemia Major Patients attending Al-Faihaa Specialized Endocrine Center at Al-Basra City
DOI:
https://doi.org/10.21070/ijhsm.v2i1.160Keywords:
Prevalence, Endocrinopathies, Beta Thalassemia MajorAbstract
Background: Endocrine disorders in patients with thalassemia are one of the most common complications, and the burden of excessive iron overload and suboptimal chelation therapy mainly causes them. The prevalence is very high; however, determining it is almost impossible due to the wide range of heterogeneity among people and the varying times of exposure to chelation agents. Aim: To find out the prevalence of endocrinopathies and their types among patients with Beta-thalassemia major. Patients and Method: A retrospective descriptive cross-sectional study, in which the data of 172 thalassemia major patients who consulted the AL-Faihaa Specialized Endocrine, Metabolism and Diabetes Center (FSEMD) during the period from the first of September 2008 to the first of July 2017, were analyzed, and the results were obtained. Results: The study showed that out of 172 patients with Beta-thalassemia major, endocrinopathies were reported in 165 (95.9%) of them. Growth hormone (GH) deficiency, secondary Hypoparathyroidism, non-insulin-dependent diabetes mellitus (NIDDM), and hypogonadism were the commonest endocrine complications. Age of the patient and duration of disease were primary risk factors significantly affecting the prevalence of these complications.
Highlights :
- High Prevalence of Endocrinopathies: 95.9% of Beta-thalassemia major patients had at least one form of endocrine disorder, indicating it as a major complication.
- Common Types Identified: Growth hormone deficiency, secondary hypoparathyroidism, non-insulin-dependent diabetes mellitus, and hypogonadism were the most frequent endocrinopathies.
-
Risk Factors: Older age and longer disease duration were significantly associated with a higher prevalence of these endocrine complications.
Keywords: Prevalence, Endocrinopathies, Beta Thalassemia Major
References
[1] J. Chapin and P. J. Giardina, "Thalassemia syndromes," Hematology, pp. 546-570. e10, 2018.
[2] R. Galanello and R. Origa, "Beta-thalassemia," Orphanet journal of rare diseases, vol. 5, pp. 1-15, 2010.
[3] T. Surapon, "Thalassemia syndrome," Advances in the study of genetic disorders, vol. 21, pp. 101-48, 2011.
[4] C. Borgna and R. Galanello, "Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis," in Wintrobe's Clinical Hematology 3° ED, ed: Lippincott Williams & Wilkins, 2009, pp. 1083-1131.
[5] A. A. Hagag, M. S. Elfrargy, R. A. Gazar, and A. E. Abd El-Lateef, "Therapeutic value of combined therapy with deferasirox and silymarin on iron overload in children with beta thalassemia," Mediterranean journal of hematology and infectious diseases, vol. 5, p. e2013065, 2013.
[6] A. R. Cohen, "New advances in iron chelation therapy," ASH Education Program Book, vol. 2006, pp. 42-47, 2006.
[7] M. Bhatia and M. Walters, "Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future," Bone marrow transplantation, vol. 41, pp. 109-117, 2008.
[8] M. F. Murphy and S. J. Stanworth, "Haematological disease," Practical Transfusion Medicine, pp. 308-319, 2009.
[9] V. Di Marco, M. Capra, F. Gagliardotto, Z. Borsellino, D. Cabibi, F. Barbaria, et al., "Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C," haematologica, vol. 93, pp. 1243-1246, 2008.
[10] N. F. Olivieri and D. J. Weatherall, "Clinical aspects of beta thalassemia and related disorders," Disorders of hemoglobin, vol. 2, pp. 357-416, 2009.
[11] P. Portincasa, A. Moschetta, M. Berardino, A. Di Ciaula, M. Vacca, G. Baldassarre, et al., "Impaired gallbladder motility and delayed orocecal transit contribute to pigment gallstone and biliary sludge formation in β-thalassemia major adults," World Journal of Gastroenterology: WJG, vol. 10, p. 2383, 2004.
[12] E. M. Erfurth, H. Holmer, P.-G. Nilsson, and B. Kornhall, "Is growth hormone deficiency contributing to heart failure in patients with beta-thalassemia major?," European journal of endocrinology, vol. 151, pp. 161-166, 2004.
[13] P. B. Walter, E. A. Macklin, J. Porter, P. Evans, J. L. Kwiatkowski, E. J. Neufeld, et al., "Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial," haematologica, vol. 93, pp. 817-825, 2008.
[14] J. Papadimas, D. G. Goulis, E. Mandala, G. Georgiadis, V. Zournatzi, B. C. Tarlatzis, et al., "B-thalassemia and gonadal axis: a cross-sectional, clinical study in a Greek population," Hormones, vol. 1, pp. 179-187, 2002.
[15] M. G. Vogiatzi, E. A. Macklin, F. L. Trachtenberg, E. B. Fung, A. M. Cheung, E. Vichinsky, et al., "Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America," British journal of haematology, vol. 146, pp. 546-556, 2009.
[16] E. A. Rachmilewitz and P. J. Giardina, "How I treat thalassemia," Blood, The Journal of the American Society of Hematology, vol. 118, pp. 3479-3488, 2011.
[17] M. R. Gamberini, V. De Sanctis, and G. Gilli, "Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre," Pediatric endocrinology reviews: PER, vol. 6, pp. 158-169, 2008.
[18] W.-Y. Au, W. W.-M. Lam, W. Chu, S. Tam, W.-K. Wong, R. Liang, et al., "A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major," Haematologica, vol. 93, pp. 116-119, 2008.
[19] R. A. De Assis, A. A. F. Ribeiro, F. U. Kay, L. A. Rosemberg, C. H. Nomura, S. R. Loggetto, et al., "Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients," European journal of radiology, vol. 81, pp. 1465-1470, 2012.
[20] F. Mojtahedzadeh, M. KOUSARIAN, M.-R. Mahdavi, and J. Akbari, "The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial," 2006.
[21] H. H. Elsedfy, M. El Kholy, R. Hamza, A. Hamed, and M. Elalfy, "Adrenal function in thalassemia major adolescents," Pediatric Endocrinology Reviews: PER, vol. 8, pp. 295-299, 2011.
[22] E. B. Fung, P. R. Harmatz, P. D. Lee, M. Milet, R. Bellevue, M. R. Jeng, et al., "Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell disease," British journal of haematology, vol. 135, pp. 574-582, 2006.
[23] A. M. Tiryag and H. H. Atiyah, "Nurses' knowledge toward obesity in al-Basra city," Annals of the Romanian Society for Cell Biology, vol. 25, pp. 4667-4673, 2021.
[24] V. De Sanctis, A. Eleftheriou, and C. Malaventura, "Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF)," Pediatric endocrinology reviews: PER, vol. 2, pp. 249-255, 2004.
[25] S. K. Jassim, Z. Abbass, and A. M. Tiryag, "A Study of Diabetes Correlated Emotional Distress among Patients with Type 2 Diabetes Mellitus: A cross Sectional Study," Academia Open, vol. 9, pp. 10.21070/acopen. 9.2024. 10292-10.21070/acopen. 9.2024. 10292, 2024.
[26] A. M. Tiryag and H. H. Atiyah, "Nurses’ knowledge toward bariatric surgery at surgical wards at teaching hospitals in Al-Basra city," Indian Journal of Forensic Medicine & Toxicology, vol. 15, pp. 5152-5159, 2021.
[27] E. H. Rahi, Z. M. H. Al-Hejaj, and A. M. Tiryag, "Nurses' knowledge of nonalcoholic fatty liver disease: A cross-sectional study," Academia Open, vol. 9, pp. 10.21070/acopen. 9.2024. 10306-10.21070/acopen. 9.2024. 10306, 2024.
[28] A. Tiryag, "Revitalizing hearts: The transformative impact of pacemaker therapy on cardiac conduction disorders," Academia Open, vol. 9, pp. 10-21070, 2024.
[29] H. M. Sabty, S. B. Dawood, and A. M. Tiryag, "Nurses’ knowledge and practices on influenza vaccination for pregnant women," Jurnal Kebidanan Midwiferia, vol. 10, pp. 50-59, 2024.
[30] M. Akber, A. Tiryag, and A. Alobaidi, "Nurses’ knowledge regarding cast complications of limb fractures: A cross-sectional study," Central Asian Journal of Medical and Natural Science, vol. 5, pp. 195-200, 2024.
[31] M. A. Akber, A. M. Tiryag, and A. Alobaidi, "Nurses’ knowledge concerning developmental dysplasia of the hip: A cross-sectional study," American Journal of Pediatric Medicine and Health Sciences, vol. 2, pp. 155-160, 2024.
[32] M. A. Mohammad, A. Y. Al-Timary, and A. M. Tiryag, "Safety of Tubeless Double Access Percutaneous Nephrolithotomy Compared to Single Access Approach," Bahrain Medical Bulletin, vol. 45, 2023.
[33] I. Zainel, H. Abdul-Ra'aoof, and A. Tiryag, "Mothers' knowledge and attitudes towards her children with neonatal jaundice: A cross-sectional study," Health Education and Health Promotion, vol. 10, pp. 565-570, 2022.
[34] S. S. Hamid, A. F. Kareem, A. M. Tiryag, and H. H. Abdul-Ra’aoof, "A Study Regarding the Basic Anatomy and Physiology of the Eye among Nursing Students: A Cross-Sectional Study: Studi Mengenai Anatomi dan Fisiologi Dasar Mata di Kalangan Mahasiswa Keperawatan: Sebuah Studi Cross-Sectional," Indonesian Journal on Health Science and Medicine, vol. 2, 2025.
[35] A. M. Tiryag, "Nurses’ Knowledge and Attitudes Toward Pacemaker: A Cross-Sectional Study," Academia Open, vol. 9, pp. 10.21070/acopen. 9.2024. 8845-10.21070/acopen. 9.2024. 8845, 2024.
[36] F. A. Jassim, A. M. Tiryag, and S. S. Issa, "Effect of bad habits on the growth of school students: A cross-sectional study," Indonesian Journal on Health Science and Medicine, vol. 1, pp. 10-21070, 2024.
[37] M. Toumba, A. Sergis, C. Kanaris, and N. Skordis, "Endocrine complications in patients with Thalassaemia Major," Pediatric endocrinology reviews, vol. 5, p. 642, 2007.
[38] A. A. Shamshirsaz, M. R. Bekheirnia, M. Kamgar, N. Pourzahedgilani, N. Bouzari, M. Habibzadeh, et al., "Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran," BMC endocrine disorders, vol. 3, pp. 1-6, 2003.
[39] W.-A. Mula-Abed, H. Al Hashmi, M. Al Muslahi, H. Al Muslahi, and M. Al Lamki, "Prevalence of endocrinopathies in patients with Beta-thalassaemia major-a cross-sectional study in oman," Oman medical journal, vol. 23, p. 257, 2008.
[40] R. H. Merchant, A. Shirodkar, and J. Ahmed, "Evaluation of growth, puberty and endocrine dysfunctions in relation to iron overload in multi transfused Indian thalassemia patients," The Indian Journal of Pediatrics, vol. 78, pp. 679-683, 2011.
[41] A. M. Habeb, Z. M. Al-Hawsawi, M. M. Morsy, A. M. Al-Harbi, A. S. Osilan, M. S. Al-Magamsi, et al., "Endocrinopathies in beta-thalassemia major. Prevalence, risk factors, and age at diagnosis in Northwest Saudi Arabia," Saudi medical journal, vol. 34, pp. 67-73, 2013.
[42] M. Jabbar, M. Mohammad, and A. Tiryag, "Changes in male reproductive hormones in patients with COVID-19," Georgian Medical News, vol. 342, pp. 42-46, 2023.
[43] Z. Abbass, S. K. Jassim, A.-F. Sadeq, S. Hafedh, A. M. Tiryag, and H. H. A. AL-Hadrawi, "Determination of self-efficacy level: The capacity of patients with hypertension to manage their chronic disease," Indonesian Journal on Health Science and Medicine, vol. 1, pp. 10.21070/ijhsm. v1i2. 15-10.21070/ijhsm. v1i2. 15, 2024.
[44] M. A. Mohammad, F. A. Jassim, and A. M. Tiryag, "Single-use flexible ureteroscope for the treatment of renal stone," Revista Latinoamericana de Hipertension, vol. 18, 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ghasaq K.I. Al - Hamdi, Sajjad S. Issa Issa, Abbas A. Mansur
This work is licensed under a Creative Commons Attribution 4.0 International License.
